Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis - Wikidata - awgldk - TriplyDB

Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis

Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis

http://www.wikidata.org/entity/Q34050113

about

Advances in the diagnosis and treatment of sarcoidosis Clinical highlights: messages from Munich Adalimumab-Responsive Refractory Sarcoidosis Following Multiple Eyebrow Tattoos: A Case Report.New molecular targets for the treatment of sarcoidosis.Refractory pulmonary sarcoidosis - proposal of a definition and recommendations for the diagnostic and therapeutic approach.Anti-TNFα therapy in inflammatory lung diseases.Pulmonary Sarcoidosis Induced by Adalimumab: A Case Report and Literature Review.Pulmonary Sarcoidosis following Etanercept Treatment for Ankylosing Spondylitis: A Case Report and Review of the Literature.

P2860

Q27026974-2AF8C9D8-5448-474B-8576-68B8F6E1590B Q28596781-49096B74-38DA-40A8-8B0C-219562DA23B2 Q33806476-6A27D170-7B12-4771-948D-E30071509F63 Q37494750-688716A5-53DA-4CFD-B83D-AE0BE9CB03B6 Q38773552-C316EAB2-193A-4A06-8460-0FD25F09F9CC Q39392448-451F93B8-02AC-4080-9D5E-67198229538B Q43110043-AAB95899-2112-409C-A645-C078250DA216 Q53696500-EB626AA5-C419-4810-8573-5C8377E74559

P2860

Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis

http://www.wikidata.org/entity/Q34050113

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Efficacy Results of a 52-week ...... ment of Refractory Sarcoidosis

@ast

Efficacy Results of a 52-week ...... ment of Refractory Sarcoidosis

@en

Efficacy Results of a 52-week ...... ment of Refractory Sarcoidosis

@nl

type

label

Efficacy Results of a 52-week ...... ment of Refractory Sarcoidosis

@ast

Efficacy Results of a 52-week ...... ment of Refractory Sarcoidosis

@en

Efficacy Results of a 52-week ...... ment of Refractory Sarcoidosis

@nl

prefLabel

Efficacy Results of a 52-week ...... ment of Refractory Sarcoidosis

@ast

Efficacy Results of a 52-week ...... ment of Refractory Sarcoidosis

@en

Efficacy Results of a 52-week ...... ment of Refractory Sarcoidosis

@nl

P1433

Q34050113-3C3C772F-588F-43AE-84D2-68B92DBAE873

P1476

Q34050113-226032EC-9F01-4A6B-AB9E-F2B8B887FA1A

P2093

Q34050113-07FABDF9-9683-4992-9A78-FEAE21C4817C

Q34050113-24F325E8-2B17-42F0-B982-400619BDA5FB

Q34050113-45D1B28F-6017-45C5-87E1-DB90A6AAAF27

Q34050113-649C06E4-2D8D-4843-8FD6-1100F37BC2B9

Q34050113-7498DB86-733A-43B8-8AD8-77B100F4F714

Q34050113-836E1F2E-6076-45F4-A4B3-57EA4E7C52FC

Q34050113-91FC1416-7A78-4571-AF01-47308E81476A

Q34050113-9B6DDFE6-B3B8-4EFF-83B8-B10E64F7108B

Q34050113-9C1D06CC-1D26-4FE7-95A6-7D2EE0A71461

Q34050113-AD916A05-6E68-452B-8BD1-F79F7FD45A7F

P2860

Q34050113-1D9A635A-7220-49E4-894D-3CDA9805FDB9

Q34050113-249FA744-385A-4E38-A30F-47EDD820D1F0

Q34050113-2FDC15D8-0A68-4E79-89B4-8D2E8E55C66C

Q34050113-3282157F-C2EA-4095-8971-0184CEBDF26D

Q34050113-34ED41D9-7B07-42BD-8CA8-567591EE8F62

Q34050113-383FF44C-3871-4A7B-B781-CA8A227A35ED

Q34050113-48D6BF6B-BDCF-499C-9D30-5AA747FC91A0

Q34050113-545CF692-7E71-46A6-9F8D-B47CAE7F3BBF

Q34050113-6AC5F2AB-6D9E-4F97-91C7-AB075CD2AAA9

Q34050113-917FA979-0F27-40E0-BAAE-782CF8556CCA

P304

Q34050113-BB2C3636-6FAB-439A-8E4A-7F0559D566BE

P31

Q34050113-4ADF16D0-293F-4EFE-A138-66FCC8074B69

P433

Q34050113-59B4055C-FBE2-4C10-97AD-473830EE4E18

P478

Q34050113-BC5764AF-C76F-4E6F-8269-EC446F671F6D

P577

Q34050113-22D50137-D7CA-4FCA-96FA-6573D23FF22C

P698

Q34050113-1F782D70-531D-4618-A997-C29E1F556B6E

P921

Q34050113-9FF9DF3E-E621-466B-8791-E00D4EAE4865

P932

Q34050113-21DD99B5-73B5-4768-BCCC-88537F008F0A

P1433

Sarcoidosis Vasculitis and Diffuse Lung Diseases

P1476

Efficacy Results of a 52-week ...... ment of Refractory Sarcoidosis

@en

P2093

Aileen L Pangan

http://www.w3.org/2001/XMLSchema#string

D Kyle Hogarth

http://www.w3.org/2001/XMLSchema#string

Edward T Naureckas

http://www.w3.org/2001/XMLSchema#string

Imre Noth

http://www.w3.org/2001/XMLSchema#string

Joe G N Garcia

http://www.w3.org/2001/XMLSchema#string

Mary Strek

http://www.w3.org/2001/XMLSchema#string

Mehdi Mirsaeidi

http://www.w3.org/2001/XMLSchema#string

Nadera J Sweiss

http://www.w3.org/2001/XMLSchema#string

Philip Caligiuri

http://www.w3.org/2001/XMLSchema#string

Robert P Baughman

http://www.w3.org/2001/XMLSchema#string

P2860

A concise review of pulmonary sarcoidosis

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data.

A case control etiologic study of sarcoidosis: environmental and occupational risk factors.

Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement.

Perceived exertion as an indicator of somatic stress.

Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization.

Linkage of type I interferon activity and TNF-alpha levels in serum with sarcoidosis manifestations and ancestry

Disfiguring annular sarcoidosis improved by adalimumab.

P304

46-54

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P577

2014-04-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24751453

http://www.w3.org/2001/XMLSchema#string

P921

P932

4134103

http://www.w3.org/2001/XMLSchema#string